Results 21 to 30 of about 31,441 (216)

Isolation and characterization of an apoA-II-containing lipoprotein (LP-A-II:B complex) from plasma very low density lipoproteins of patients with Tangier disease and type V hyperlipoproteinemia.

Journal of Lipid Research, 1991
Previous studies have shown that very low density lipoproteins (VLDL) from patients with Tangier disease are less effective as a substrate for human milk lipoprotein lipase (LPL) than VLDL from normal controls as assessed by measuring the first order ...
P Alaupovic, C Knight-Gibson, CS Wang, D Downs, E Koren, HB Brewer, Jr, RE Gregg   +6 more
doaj   +1 more source

D4F alleviates macrophage-derived foam cell apoptosis by inhibiting CD36 expression and ER stress-CHOP pathway[S]

Journal of Lipid Research, 2015
This study was designed to explore the protective effect of D4F, an apoA-I mimetic peptide, on oxidized LDL (ox-LDL)-induced endoplasmic reticulum (ER) stress-CCAAT/enhancer-binding protein (C/EBP) homologous protein (CHOP) pathway-mediated apoptosis in ...
Shutong Yao, Hua Tian, Cheng Miao, Da-Wei Zhang, Li Zhao, Yanyan Li, Nana Yang, Peng Jiao, Hui Sang, Shoudong Guo, Yiwei Wang, Shucun Qin   +11 more
doaj   +1 more source

MicroRNAs and Atherosclerosis [PDF]

Current Atherosclerosis Reports, 2013
MicroRNAs (miRNAs) are small, ~22 nucleotide (nt) sequences of RNA that regulate gene expression at posttranscriptional level. These endogenous gene expression inhibitors were primarily described in cancer but recent exciting findings have also demonstrated a key role in cardiovascular diseases (CVDs), including atherosclerosis.
Julio, Madrigal-Matute, Noemi, Rotllan, Juan F, Aranda, Carlos, Fernández-Hernando   +3 more
openaire   +2 more sources

Circulating Markers Reflect Both Anti- and Pro-Atherogenic Drug Effects in ApoE-Deficient Mice

Biomarker Insights, 2008
Background Current drug therapy of atherosclerosis is focused on treatment of major risk factors, e.g. hypercholesterolemia while in the future direct disease modification might provide additional benefits.
Birong Liao, Eileen McCall, Karen Cox, Chung-Wein Lee, Shuguang Huang, Richard E Higgs, Li-Chun Chio, Eugene Zhen, John E Hale, Nancy K Jackson, Pamela G Rutherford, Xiao-di Huang, Donetta Gifford-Moore, Kwan Hui, Kevin Duffin, Kenneth E Gould, Mark Rekhter   +16 more
doaj   +1 more source

Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system

FEBS Letters, EarlyView.
Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley   +1 more source

Effect of dietary cholesterol and taurocholate on cholesterol 7 alpha-hydroxylase and hepatic LDL receptors in inbred mice

Journal of Lipid Research, 1993
Compared to BALB/c mice, inbred C57BL/6 mice are more susceptible to developing fatty streak atherosclerotic lesions when fed a cholesterol-rich diet containing taurocholate. We examined the metabolic basis for the taurocholate requirement.
S Dueland, J Drisko, L Graf, D Machleder, AJ Lusis, RA Davis   +5 more
doaj   +1 more source

Cyclic azapeptide CD36 ligand attenuates cardiac injury and reduces long‐chain fatty acid accumulation after myocardial ischemia–reperfusion in mice

FEBS Open Bio, EarlyView.
In a murine model of myocardial ischemia and reperfusion (MI/R), the CD36 azapeptide ligand MPE‐298 reduces cardiac injury and transiently lowers left ventricular long‐chain fatty acids (LCFAs) accumulation 3 h after reperfusion, accompanied by a decrease of oxidative stress and inflammation‐associated genes' expression in the heart and adipose tissue.
Jade Gauvin, Naghme Radmannia, David N. Huynh, Liliane Ménard, Caroline Daneault, Maïté Veilleux, Ahsanullah Ahsanullah, André C. Carpentier, William D. Lubell, Matthieu Ruiz, Huy Ong, Sylvie Marleau, Simon‐Pierre Gravel   +12 more
wiley   +1 more source

Mouse models to study von Willebrand factor in inflammation: a scoping review

Intensive Care Medicine Experimental
Background VWF is released from activated endothelial cells and activated platelets in response to vascular injury, and is now recognized as an important contributor to a growing number of inflammatory conditions. This scoping review aims to identify and
Hassan Masood, Veronica DeYoung, Peter Andrisani, Arthane Kodeeswaran, Taylor Sparring, Jaskirat Arora, Natasha Savic, Jonathan L. Babulic, Davide Matino, Patricia Y. Liaw, Colin A. Kretz, Alison Fox-Robichaud   +11 more
doaj   +1 more source

Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants [version 1; referees: 2 approved]

F1000Research, 2017
The direct oral anticoagulants (DOACs) have now supplanted vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE). The DOACs include dabigatran, which inhibits thrombin, and rivaroxaban, apixaban, and edoxaban, which inhibit ...
Jeffrey I. Weitz, Iqbal H. Jaffer, James C. Fredenburgh   +2 more
doaj   +1 more source

UiO‐66 metal–organic frameworks in biomedicine: From structural tunability to bioimaging, photodiagnostics, and photodynamic cancer therapy

FEBS Open Bio, EarlyView.
UiO‐66(Zr) metal–organic frameworks are chemically stable, biocompatible, and highly tunable nanomaterials. Their modular structure enables controlled drug delivery, multimodal bioimaging, and light‐activated photodynamic therapy, supporting integrated diagnostic and therapeutic (theranostic) applications in cancer and biomedical research.
Veronika Huntošová, Grigorii Rakhalskii, Miroslav Almáši   +2 more
wiley   +1 more source